论文部分内容阅读
目的:探讨替吉奥作为晚期老年胃癌患者一线化疗的疗效和安全性。方法:收集我科2010.2-2014.10接受替吉奥单药化疗的晚期老年胃癌患者共计62例。替吉奥单药用法为每次40mg,每天2次,连续14天,21天一个周期,连用2周期后评价疗效。结果:替吉奥单药的疾病控制率为62.9%,有效率为17.7%,主要不良反应为中性粒细胞下降,神经毒性,手足综合症,恶心,呕吐,腹泻,经对症治疗后均可好转,无治疗相关性死亡。结论:替吉奥单药治疗晚期老年胃癌效果较好,耐受性良好。“,”Objective:To investigate the ef icacy and safety of S1 as first -line treatment in elderly patients with advanced gastric cancer Methods:Sixty -two elderly patients with advanced gastric cancer were col ected from Feb 2010 to Oct 2014.Al patients received S1 chemotherapy,S1 40mg was given oral y,twice daily on days 1 to 14 fol owed by one week rest period,the cycle was repeated every three weeks.Assessment of the response was made after two cycles. Results:The disease control rate was 62.9% and the overal objective response rate was 17.7% in the S1 group.The major adverse ef ect in the S1 group included leucocytopenia,neurop-athy,hand and foot syndrome,nause,vomiting and diarrhea. Conclusions:S1 of ers an ef ective,safe and wel -tolerated regimen for e elderly patients with gastric cancer.